Morgan Stanley Hepion Pharmaceuticals, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.31 - $1.06 $2,422 - $8,281	7,813 Added 9.72%	88,216 $68,000
Q4 2022 Feb 14, 2023	BUY	$0.27 - $11.9 $17,008 - $749,652	62,996 Added 361.9%	80,403 $24,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $4,198 - $85,623	-8,233 Reduced 32.11%	17,407 $8,000
Q2 2022 Oct 27, 2022	SELL	$0.57 - $1.22 $6,796 - $14,546	-11,923 Reduced 31.74%	25,640 $15,000
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.22 $6,796 - $14,546	-11,923 Reduced 31.74%	25,640 $15,000
Q1 2022 Oct 27, 2022	BUY	$0.93 - $1.29 $11,088 - $15,380	11,923 Added 46.5%	37,563 $48,000
Q1 2022 May 13, 2022	BUY	$0.93 - $1.29 $392 - $544	422 Added 1.14%	37,563 $48,000
Q4 2021 Feb 14, 2022	BUY	$1.14 - $1.58 $2,399 - $3,325	2,105 Added 6.01%	37,141 $42,000
Q3 2021 Nov 15, 2021	BUY	$1.39 - $2.1 $48,700 - $73,575	35,036 New	35,036 $54,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $57.2M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.